Building tomorrow's antibody-drug conjugates (ADCs)

Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology. Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering. Learn more

Antibody-drug conjugate (ADC)

ADCs are powerful biopharmaceuticals, delivering highly potent drugs very specifically to the desired tissue

ADCs consist of highly potent cytotoxic agents conjugated to antibodies through a specific linker. This molecular format enables the highly selective delivery of any payload to the diseased tissue, while healthy parts of the human body are spared. To date, ADCs generated with conventional methods have faced the following challenges:

Our solution: Araris Linker Technology

We are pioneering a technology enabling fast and precise production of ADCs. Our innovative approach has the potential to set new benchmarks in terms of development, analysis and performance. The following properties contribute to the high efficacy and low level of toxicity observed so far with our ADCs:

Figure

Parent antibody can be used ‘off-the-shelf’

No need for engineering or antibody reduction.

  • reduced cost and time for ADC development – less than 2 days for payload attachment
  • amenable to high-throughput screening
  • clear defined drug-to-antibody-ratio (DAR2 or DAR4) obtained

Araris LINKERs show excellent solubility (hydrophilic) and offer an unparalleled chemical versatility

  • Enables any payload to be conjugated to any antibody without major optimization
  • Straightforward incorporation of chemical functional (reactive) groups into the linker to attach payloads by different means (azide, sulfhydryl et.) thanks to its peptidic nature

Araris ADCs are very stable in serum and under stressed conditions

This may lead to lower dosing, higher efficacy and lower risk for side effects.

Araris team

Philipp Spycher

Philipp Spycher Co-founder and CEO (Board, Management team)

As the inventor of the Araris Linker Technology, Philipp has a profound background in Bioconjugation and ADCs. He obtained his Master’s Degree and PhD from ETH Zurich at the interface of Material Science and Protein Engineering. During his post-doctoral work at PSI, he introduced the novel approach using transglutaminases for antibody conjugation that led to the discovery of the Araris Linker Technology.

Isabella Attinger-Toller

Isabella Attinger-Toller Co-founder and VP Translational Research (Management team)

Isabella holds a Master’s Degree in Molecular Biology from University of Basel and obtained a PhD in Tumorimmunology from University of Zurich (UZH). Before joining Araris, she served as Director Pharmacology at Covagen, a Swiss Biotech that was acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical companies of Johnson & Johnson. She was in charge of the pharmacological characterization of various FynomAbs during pre-clinical development that entered clinical testing.

Dragan Grabulovski

Dragan Grabulovski Co-founder and Chairman (Board)

Dragan received his Master’s degree and PhD in Pharmaceutical Sciences from ETH Zürich. From 2007 to 2014 he was co-founder and CSO of Covagen, a Swiss biotech company acquired in 2014 by an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. He was instrumental in Covagen’s trade sale to Johnson & Johnson, in establishing deals with Roche and Mitsubishi Tanabe and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014. Since 2015 he is a serial entrepreneur and Biotech consultant at Grabulovski Consulting Services.

We are backed by a strong investor syndicate: redalpine | Schroder Adveq | VI Partners

What's new

Araris chosen as one of the "Venture Leaders Life Sciences 2020" winners 22/04/20

We are very proud to be chosen among 60 high quality applicants and are looking forward to the experience and learing on the roadshow in Boston. 

Clinical-stage Transglutaminase company Zedira releases article on Araris Technology 20/02/20

Zedira published a high level summary on the core of the Araris Linker Technology.

Contact

Araris Biotech AG, c/o ETH Zürich Otto-Stern-Weg 7, 8093, Zürich, Switzerland

How to get to us